^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SIK3 inhibitor

    Related drugs:
    Apply
    Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (NCT05239910)
    Phase 2
    Rhizen Pharmaceuticals SA
    Withdrawn
    Last update posted :
    10/17/2022
    Initiation :
    01/01/2023
    Primary completion :
    12/01/2026
    Completion :
    05/01/2027
    ALK • TNFRSF8
    |
    ALK positive
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • tenalisib (RP6530)